Mar 16, 2023 / 08:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Sarepta Therapeutics SRP-9001 BLA update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Doug Ingram, President and Chief Executive Officer. Please go ahead, sir.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you, Norma. Good evening, and thank you for joining our update call regarding the Biologics License Application, or BLA, for SRP-9001, our investigational gene therapy to treat Duchenne muscular dystrophy. As you will have seen in our accompanying release, we completed our late-cycle review this week and the FDA's Office of Therapeutic Products, or OTP, has now determined that they will hold an advisory committee, or Adcom, meeting for the SRP-9001 BLA.
As Duchenne muscular dystrophy is a devastating and life-ending disease and time is of the essence for the thousands of families living with Duchenne, the Center for Biologics
Sarepta Therapeutics Inc SRP-9001 BLA Update Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers